Key points from article :
Fractyl, an obesity drug developer, raised $110 million in its IPO.
They nominated RJVA-001, a gene therapy for obesity and type 2 diabetes aiming for longer-lasting effects than current treatments.
Early animal studies showed promising results for blood sugar control and weight loss.
Fractyl plans to start testing RJVA-001 in humans later in 2024.
They also have another therapy, Revita, in trials for type 2 diabetes and weight management.
